Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



Absolute Antibody Launches VivopureX™ Recombinant Antibodies for In Vivo Research

Redcar, UK, January 7, 2020. Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced the launch of its VivopureX™ recombinant mouse antibodies for in vivo research in mouse models.

Read the rest of entry »

Efficient Isolation of Circulating Cell Free DNA

AMSBIO has expanded its range of cfPure™ Cell Free DNA Purification Kits for rapid and efficient isolation of circulating cell free DNA (cfDNA).  A new cfPure™Max kit is now available for use on samples of 5mLs volume or greater.

Read the rest of entry »

RSSL's First QP Connect Symposium

RSSL is proud to announce that its first QP Connect Symposium, held in conjunction with the PHSS, is to be held 12th May 2020.

Read the rest of entry »

Understanding the 3D shape of Oligodendrocytes

AMSBIO reports on the pioneering research published** by scientists at Stanford University Medical School that has cited Mimetix® aligned 3D cell culture scaffold supplied by the company to understand the architecture of the myelin sheaths which insulate neuronal axons, so they can transmit electrical impulses quickly and efficiently.
 

Read the rest of entry »

Pathios Therapeutics closes US$8.8M Series A and appoints Stuart Hughes as CEO

OXFORD, UK 18th DECEMBER 2019: Pathios Therapeutics Limited (“Pathios”), an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare investors Canaan and Australia’s Medical Research Commercialisation Fund managed by Brandon Capital (“MRCF”). 

Read the rest of entry »

Arctoris Ltd Successfully Moves into its New Global Headquarters in Oxford, UK

OXFORD, UK – 11th December 2019 – Arctoris Ltd, the developer of the world’s first fully automated drug discovery platform, today opened the doors to its new global headquarters and state-of-the-art research and development (R&D) facility in Oxford, UK. Housing the company’s proprietary technology and providing space for its rapidly growing commercial and scientific teams, the facility will enable Arctoris to continue to support its research partners around the world with its structured, automated approach to drug discovery.

Read the rest of entry »

AMSBIO: 3D Cell Culture Proves Invaluable to Myelination Research

AMSBIO reports on the pioneering research published** by scientists at Stanford University Medical School that has cited Mimetix® aligned 3D cell culture scaffold supplied by the company to understand the architecture of the myelin sheaths which insulate neuronal axons, so they can transmit electrical impulses quickly and efficiently.

Read the rest of entry »

Upperton is Launching an Enabling Technology Screening Protocol

Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO) are launching a platform which aims to support companies with the rapid development of both standard and complex drug products.

Read the rest of entry »

The Oxford Science Park: Green light for planning permission at Plot 16 as The Oxford Science Park continues ambitious expansion plans 

Oxford, UK, December 5 2019 - Oxford City Council’s East Area Planning Committee has approved the detailed plans for two office / laboratory buildings on The Oxford Science Park’s Plot 16 comprising 168,000 sq ft (15,600 sq m).  The plans feature a central raised plaza and wider landscaping and accessibility enhancements. 

Read the rest of entry »

Arecor announces positive headline results for the first Phase I clinical trial of AT247, a novel ultra rapid acting formulation of insulin

Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247.  In the study, AT247 provided a favourable pharmacokinetic/pharmacodynamic profile compared with NovoRapid® and Fiasp®.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

https://0123movie.net
izmir sınırsız escort Betboo
konak escort alsancak escort side escort antalya grup escort antalya grup escort ankara rus escort
antalya sınırsız escort sakarya sınırsız escort